Development and validation of immunoassays for novel immunotherapy drugs such as KEYTRUDA (pembrolizumab), OPDIVO (nivolumab) and YERVOY (ipilimumab), for monitoring drug levels in patients with lung cancer and malignant melanoma.
Developing assays for measuring different monoclonal antibodies used in the treatment of patients with autoimmune diseases. These assays are used in the clinical routine and in several ongoing clinical trials.
Detection of antibodies to transglutaminase in the HUNT4-cohort using an in-house dual label assay in collaborative study “Coeliac disease in HUNT”.
Late effects after testicular cancer; thyroid and kidney function, in collaboration with National Advisory Unit on Late Effects after Cancer Treatment.
Screening for patient antibodies to HH1, a novel antibody-based drug used in lymphoma clinical trials (Lymrit).
Part of the collaboration study “Hallmarks in lung cancer”; validating different markers for potential development of assays clinically useful indaily practice.
Investigating the potential effect of combinatorial treatment of melanoma with PLX4032 (vemurafenib) and HER antibodies (in vitro studies).
Validating immunoassays for human epidermal growth factor receptors 2, 3 and 4 as tumour markers for HER2 positive breast cancer.
Recent publications
Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJet al.(2020) Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials BioDrugs(in press) DOI 10.1007/s40259-020-00438-7, PubMed 32965617
Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H(2020) Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma Blood Adv, 4(17), 4091-4101 DOI 10.1182/bloodadvances.2020002583, PubMed 32877524
Buhl S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C(2020) Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease Scand J Gastroenterol, 55(8), 884-890 DOI 10.1080/00365521.2020.1786852, PubMed 32631131